JP2010539242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539242A5 JP2010539242A5 JP2010525966A JP2010525966A JP2010539242A5 JP 2010539242 A5 JP2010539242 A5 JP 2010539242A5 JP 2010525966 A JP2010525966 A JP 2010525966A JP 2010525966 A JP2010525966 A JP 2010525966A JP 2010539242 A5 JP2010539242 A5 JP 2010539242A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- patient
- compound
- receptor
- promoting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 5
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 4
- 108010077895 Sarcosine Proteins 0.000 claims description 4
- 229960001214 clofibrate Drugs 0.000 claims description 4
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 229940043230 sarcosine Drugs 0.000 claims description 4
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 claims description 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 3
- 229960000516 bezafibrate Drugs 0.000 claims description 3
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 3
- 229960002174 ciprofibrate Drugs 0.000 claims description 3
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 claims description 3
- 229960002297 fenofibrate Drugs 0.000 claims description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003627 gemfibrozil Drugs 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 102000004980 Dopamine D2 Receptors Human genes 0.000 claims description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000003042 antagnostic effect Effects 0.000 claims description 2
- 229960005049 clofibride Drugs 0.000 claims description 2
- CXQGFLBVUNUQIA-UHFFFAOYSA-N clofibride Chemical compound CN(C)C(=O)CCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 CXQGFLBVUNUQIA-UHFFFAOYSA-N 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 5
- 102000023984 PPAR alpha Human genes 0.000 description 4
- JLRNKCZRCMIVKA-UHFFFAOYSA-N Simfibrate Chemical compound C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 JLRNKCZRCMIVKA-UHFFFAOYSA-N 0.000 description 2
- 229960004058 simfibrate Drugs 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97367407P | 2007-09-19 | 2007-09-19 | |
| PCT/US2008/076842 WO2009039266A1 (en) | 2007-09-19 | 2008-09-18 | Methods of increasing sarcosine levels for treating schizophrenia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010539242A JP2010539242A (ja) | 2010-12-16 |
| JP2010539242A5 true JP2010539242A5 (enExample) | 2012-11-22 |
Family
ID=39970955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525966A Withdrawn JP2010539242A (ja) | 2007-09-19 | 2008-09-18 | サルコシンレベルを増大させる方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110034551A1 (enExample) |
| EP (1) | EP2200604A1 (enExample) |
| JP (1) | JP2010539242A (enExample) |
| AU (1) | AU2008302225A1 (enExample) |
| CA (1) | CA2699561A1 (enExample) |
| WO (1) | WO2009039266A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002243883A1 (en) * | 2001-02-07 | 2002-08-19 | The Mclean Hospital Corporation | Cholesterol-lowering agents as treatment for psychological and cognitive disorders |
| US20060039890A1 (en) * | 2004-08-20 | 2006-02-23 | Renshaw Perry F | Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant |
| WO2006034485A2 (en) * | 2004-09-21 | 2006-03-30 | The Johns Hopkins University | Treatment for age-related cognitive decline and other conditions |
| EP1871165B1 (en) * | 2005-04-11 | 2017-06-21 | Yale University | Method of treating schizophrenia prodrome |
| EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
-
2008
- 2008-09-18 JP JP2010525966A patent/JP2010539242A/ja not_active Withdrawn
- 2008-09-18 EP EP08831902A patent/EP2200604A1/en not_active Withdrawn
- 2008-09-18 AU AU2008302225A patent/AU2008302225A1/en not_active Abandoned
- 2008-09-18 CA CA2699561A patent/CA2699561A1/en not_active Abandoned
- 2008-09-18 US US12/678,614 patent/US20110034551A1/en not_active Abandoned
- 2008-09-18 WO PCT/US2008/076842 patent/WO2009039266A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
| JP2012520883A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| Li et al. | Effect of calcium channel blockade or angiotensin-converting enzyme inhibition on structure of coronary, renal, and other small arteries in spontaneously hypertensive rats | |
| DE502004010303D1 (de) | Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit | |
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| CN109982699A (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
| JP2020529995A5 (enExample) | ||
| JP2020511419A5 (enExample) | ||
| JP2009504774A5 (enExample) | ||
| JP2010539242A5 (enExample) | ||
| CN114007598A (zh) | 用于治疗病毒和细菌感染的新型mek抑制剂 | |
| JP2008534503A5 (enExample) | ||
| JP2005097255A5 (enExample) | ||
| EA200970022A1 (ru) | Комбинированные препараты, содержащие бифепрунокс и l-допу | |
| JP2013540734A5 (enExample) | ||
| NZ591328A (en) | Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof | |
| JP2009516719A5 (enExample) | ||
| AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| JP2006104186A (ja) | 感冒用医薬組成物 | |
| ES2573474T3 (es) | Composición sinérgica de compuestos analgésicos | |
| Dickson et al. | The premature invocation of a ‘gut-lung axis’ may obscure the direct effects of respiratory microbiota on pneumonia susceptibility | |
| JP2013032308A5 (enExample) | ||
| JP2009539877A5 (enExample) | ||
| JP2019512507A5 (enExample) |